Genetic Predictors of Mortality in Patients with Multiple Myeloma

References

• Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a Prospective Study. Blood. 2009;113(22):5412–5417. doi:10.1182/blood-2008-12-194241
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/jco.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Corre J, Munshi NC, Avet-Loiseau H. Risk factors in MM: is it time for a revision? Blood. 2020;135(1). doi:10.1182/blood.2019004309
   Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–172. doi:10.1056/nejm199907153410306
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. doi:10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409–421. doi:10.1038/s41571-018-0018-y
   PubMed Web of Science ®Google Scholar
• Chretien ML, Corre J, Lauwers-Cances V, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126(25):2713–2719. doi:10.1182/blood-2015-06-650242
   PubMed Web of Science ®Google Scholar
• Samur AA, Minvielle S, Shammas M, et al. Deciphering the chronology of copy number alterations in multiple myeloma. Blood Cancer J. 2019;9:1–10.
   Web of Science ®Google Scholar
• Onodera N, McCabe NR, Rubin CM. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood. 1992;80(1):203–208. doi:10.1182/blood.V80.1.203.203
   Web of Science ®Google Scholar
• Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. J Am Soc Hematol. 2001;98:2229–2238.
   Google Scholar
• Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer. 2003;38(3):234–239. doi:10.1002/gcc.10275
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562–2567. doi:10.1182/blood-2003-02-0493
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tian E, Shaughnessy JD Jr, et al. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia. 2017;31(3):637–644. doi:10.1038/leu.2016.253
   PubMed Web of Science ®Google Scholar
• Sidana S, Jevremovic D, Ketterling RP, et al. Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. Am J Hematol. 2019;94(5):E117–e120. doi:10.1002/ajh.25420
   Web of Science ®Google Scholar
• Ashby C, Tytarenko RG, Wang Y, et al. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019;10(7):732–737. doi:10.18632/oncotarget.26589
   PubMedGoogle Scholar
• Peterson JF, Rowsey RA, Marcou CA, et al. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019;9(3):20. doi:10.1038/s41408-019-0182-z
   Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170. doi:10.1038/s41375-018-0196-8
   PubMed Web of Science ®Google Scholar
• Samur MK, Shah PK, Wang X, et al. The shaping and functional consequences of the dosage effect landscape in multiple myeloma. BMC Genom. 2013;14(1):672. doi:10.1186/1471-2164-14-672
   Web of Science ®Google Scholar
• Bustoros M, Sklavenitis-Pistofidis R, Park J, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38(21):2380–2389. doi:10.1200/JCO.20.00437
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27(27):4585–4590. doi:10.1200/JCO.2008.20.6136
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–1952. doi:10.1200/jco.2011.36.5726
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol. 2006;135(4):486–491. doi:10.1111/j.1365-2141.2006.06325.x
   PubMed Web of Science ®Google Scholar
• Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl 1):117–126. doi:10.1080/10245330512331390140
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–2040. doi:10.1038/sj.leu.2404403
   PubMed Web of Science ®Google Scholar
• Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32(1):88–100.e106. doi:10.1016/j.ccell.2017.05.011
   PubMed Web of Science ®Google Scholar
• Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675–679. doi:10.1038/leu.2013.225
   PubMed Web of Science ®Google Scholar
• Ouyang J, Gou X, Ma Y, Huang Q, Jiang T. Prognostic value of 1p deletion for multiple myeloma: a meta-analysis. Int J Lab Hematol. 2014;36(5):555–565. doi:10.1111/ijlh.12189
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–4575. doi:10.1182/blood-2002-10-3017
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–1052. doi:10.1038/leu.2008.4
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–284. doi:10.1111/j.1365-2141.2004.05199.x
   PubMed Web of Science ®Google Scholar
• Corre J, Roussel M. Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients. Blood. 2020;135(1). doi:10.1182/blood.2020008346
   Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631. doi:10.1056/NEJMoa1505654
   PubMed Web of Science ®Google Scholar
• Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527. doi:10.1016/s0140-6736(16)31594-x
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Fonseca R, Siegel D, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174–1180. doi:10.1182/blood-2016-03-707596
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng W-J, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–2618. doi:10.1182/blood-2017-06-791228
   PubMed Web of Science ®Google Scholar
• Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604–2616. doi:10.1038/s41375-018-0037-9
   Web of Science ®Google Scholar
• Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. 2019;133(11):1217–1221. doi:10.1182/blood-2018-10-880831
   PubMed Web of Science ®Google Scholar
• Maura F, Bolli N, Angelopoulos N, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019;10(1):3835. doi:10.1038/s41467-019-11680-1
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40. doi:10.1016/j.cell.2010.11.055
   PubMed Web of Science ®Google Scholar
• Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5(1):2997. doi:10.1038/ncomms3997
   PubMed Web of Science ®Google Scholar
• Rustad EH, Yellapantula VD, Glodzik D, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020;1(3):258–273. doi:10.1158/2643-3230.BCD-20-0132
   Google Scholar
• González D, van der Burg M, García-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110(9):3112–3121. doi:10.1182/blood-2007-02-069625
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194(1):96–104. doi:10.1034/j.1600-065x.2003.00052.x
   Web of Science ®Google Scholar
• Hakim O, Resch W, Yamane A, et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature. 2012;484(7392):69–74. doi:10.1038/nature10909
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590. doi:10.1056/NEJMoa070389
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL, Brents LA, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88(2):674–681. doi:10.1182/blood.V88.2.674.bloodjournal882674
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Murison A, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6(1):6997. doi:10.1038/ncomms7997
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Garand R, Lodé L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570–1571. doi:10.1182/blood-2002-08-2436
   PubMed Web of Science ®Google Scholar
• Mao X-H, Zhuang J-L, Zhao -D-D, et al. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. Eur J Haematol. 2020;105(3):326–334. doi:10.1111/ejh.13440
   Web of Science ®Google Scholar
• Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene. 1992;7(7):1401–1406.
   Web of Science ®Google Scholar
• Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood. 2003;101(8):3181–3187. doi:10.1182/blood-2002-01-0263
   Web of Science ®Google Scholar
• Lakshman A, Alhaj Moustafa M, Rajkumar SV, et al. Natural history of t(11;14) multiple myeloma. Leukemia. 2018;32(1):131–138. doi:10.1038/leu.2017.204
   PubMed Web of Science ®Google Scholar
• An G, Xu Y, Shi L, et al. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res. 2013;37(10):1251–1257. doi:10.1016/j.leukres.2013.06.020
   PubMed Web of Science ®Google Scholar
• Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215–3224. doi:10.1182/blood-2016-01-688796
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409. doi:10.1182/blood-2017-06-788786
   PubMed Web of Science ®Google Scholar
• Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–1642. doi:10.1016/S1470-2045(20)30525-8
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–2400. doi:10.1182/blood-2017-06-788323
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia E, Popovic R, Min D-J, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117(1):211–220. doi:10.1182/blood-2010-07-298349
   PubMed Web of Science ®Google Scholar
• Pei H, Zhang L, Luo K, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011;470(7332):124–128. doi:10.1038/nature09658
   PubMed Web of Science ®Google Scholar
• Hebraud B, Magrangeas F, Cleynen A, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015;125(13):2095–2100. doi:10.1182/blood-2014-07-587964
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020–2028. doi:10.1182/blood-2005-11-013458
   PubMed Web of Science ®Google Scholar
• Lazareth A, Song X-Y, Coquin A, et al. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Haematologica. 2015;100(11):e471–474. doi:10.3324/haematol.2015.127001
   Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630–4634. doi:10.1200/jco.2010.28.3945
   PubMed Web of Science ®Google Scholar
• Hanamura I, Iida S, Akano Y, et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res. 2001;92(6):638–644. doi:10.1111/j.1349-7006.2001.tb01142.x
   Google Scholar
• Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191–199. doi:10.1016/s1535-6108(04)00019-4
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117(6):2009–2011. doi:10.1182/blood-2010-07-295105
   Web of Science ®Google Scholar
• Maura F, Petljak M, Lionetti M, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018;32(4):1044–1048. doi:10.1038/leu.2017.345
   Web of Science ®Google Scholar
• Shaughnessy J Jr., Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98(1):217–223. doi:10.1182/blood.v98.1.217
   Web of Science ®Google Scholar
• Prideaux SM, Conway O’Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014;2014:864058. doi:10.1155/2014/864058
   PubMedGoogle Scholar
• Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522–525. doi:10.1038/ng.2583
   Web of Science ®Google Scholar
• Ross FM, Chiecchio L, Dagrada G, et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010;95(7):1221–1225. doi:10.3324/haematol.2009.016329
   PubMed Web of Science ®Google Scholar
• Cleynen A, Szalat R, Kemal samur M, et al. Expressed fusion gene landscape and its impact in multiple myeloma. Nat Commun. 2017;8(1):1893. doi:10.1038/s41467-017-00638-w
   PubMed Web of Science ®Google Scholar
• Barwick BG, Neri P, Bahlis NJ, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun. 2019;10(1):1911. doi:10.1038/s41467-019-09555-6
   Web of Science ®Google Scholar
• Smadbeck J, Peterson JF, Pearce KE, et al. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer J. 2019;9(12):1–18. doi:10.1038/s41408-019-0255-z
   Web of Science ®Google Scholar
• Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28(8):1725–1735. doi:10.1038/leu.2014.70
   PubMed Web of Science ®Google Scholar
• Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia. Blood. 2020;34(1):322-326. Epub 2019 Aug 22. doi:10.1038/s41375-019-0543-4
   Web of Science ®Google Scholar
• Weinhold N, Kirn D, Seckinger A, et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101(3):e116–119. doi:10.3324/haematol.2015.136929
   PubMed Web of Science ®Google Scholar
• Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9(1):3363. doi:10.1038/s41467-018-05058-y
   PubMed Web of Science ®Google Scholar
• Haradhvala NJ, Polak P, Stojanov P, et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell. 2016;164(3):538–549. doi:10.1016/j.cell.2015.12.050
   Web of Science ®Google Scholar
• Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911. doi:10.1200/JCO.2014.59.1503
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Carter S, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91–101. doi:10.1016/j.ccr.2013.12.015
   PubMed Web of Science ®Google Scholar
• Samur MK, Aktas samur A, Fulciniti M, et al. Genome-wide somatic alterations in multiple myeloma reveal a Superior Outcome Group. J Clin Oncol. 2020;38(27):3107–3118. doi:10.1200/JCO.20.00461
   Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Kaiser MF, Johnson DC, Wu P, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013;122(2):219–226. doi:10.1182/blood-2013-03-487884
   PubMed Web of Science ®Google Scholar
• Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083–1093. doi:10.1016/0092-8674(89)90045-7
   PubMed Web of Science ®Google Scholar
• Lode L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95(11):1973–1976. doi:10.3324/haematol.2010.023697
   PubMed Web of Science ®Google Scholar
• Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735–1744. doi:10.1182/blood-2016-06-723007
   PubMed Web of Science ®Google Scholar
• Teoh G, Urashima M, Ogata A, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997;90(5):1982–1992. doi:10.1182/blood.V90.5.1982
   Web of Science ®Google Scholar
• Okada N, Lin CP, Ribeiro MC, et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev. 2014;28(22):438–450. doi:10.1101/gad.233585.113
   Web of Science ®Google Scholar
• Shah V, Johnson DC, Sherborne AL, et al. Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood. 2018;132(23):2465–2469. doi:10.1182/blood-2018-06-857250
   Web of Science ®Google Scholar
• Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(9):e600. doi:10.1038/bcj.2017.83
   PubMed Web of Science ®Google Scholar
• Baysal M, Demirci U, Umit E, et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep. 2020;10(1):5991. doi:10.1038/s41598-020-62885-0
   PubMed Web of Science ®Google Scholar
• Sztupinszki Z, Diossy M, Krzystanek M, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4(1):1–4. doi:10.1038/s41523-018-0066-6
   Web of Science ®Google Scholar
• Szalat R, Avet-Loiseau H, Munshi NC. Gene expression profiles in myeloma: ready for the real world? Clin Cancer Res. 2016;22:5434–5442. doi:10.1158/1078-0432.CCR-16-0867
   Web of Science ®Google Scholar
• Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du myelome. J Clin Oncol. 2008;26(29):4798–4805. doi:10.1200/JCO.2007.13.8545
   PubMed Web of Science ®Google Scholar
• Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406–2413. doi:10.1038/leu.2012.127
   PubMed Web of Science ®Google Scholar
• Zhan FH, Barlogie B, John DS Jr. Gene expression profiling defines a high-risk entity of multiple myeloma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007;32(2):191–203.
   Google Scholar
• Samur MK, Minvielle S, Gulla A, et al. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018;32(12):2626–2635. doi:10.1038/s41375-018-0116-y
   Web of Science ®Google Scholar
• Manier S, Liu C-J, Avet-Loiseau H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129(17):2429–2436. doi:10.1182/blood-2016-09-742296
   PubMed Web of Science ®Google Scholar
• Agirre X, Castellano G, Pascual M, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 2015;25(4):478–487. doi:10.1101/gr.180240.114
   Web of Science ®Google Scholar
• Marango J, Shimoyama M, Nishio H, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111(6):3145–3154. doi:10.1182/blood-2007-06-092122
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Kaiser MF, Heuck C, et al. The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clin Cancer Res. 2016;22(23):5783–5794. doi:10.1158/1078-0432.CCR-15-1790
   Web of Science ®Google Scholar
• Mason MJ, Schinke C, Eng CLP, et al. Multiple myeloma DREAM challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020;34(7):1866–1874. doi:10.1038/s41375-020-0742-z
   PubMed Web of Science ®Google Scholar
• Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene. 2005;24(41):6269–6280. doi:10.1038/sj.onc.1208771
   PubMed Web of Science ®Google Scholar
• Neo WH, Lim JF, Grumont R, Gerondakis S, Su I-H. c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells. J Biol Chem. 2014;289(46):31693–31707. doi:10.1074/jbc.M114.574517
   Web of Science ®Google Scholar
• Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H. Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. Leukemia. 2018;32(11):2471–2482. doi:10.1038/s41375-018-0140-y
   Web of Science ®Google Scholar
• Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H. EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomarker Res. 2018;6(1):1–10. doi:10.1186/s40364-018-0148-5
   Web of Science ®Google Scholar
• Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget. 2018;9(31):21930. doi:10.18632/oncotarget.25128
   Google Scholar
• Nylund P, Atienza Párraga A, Haglöf J, et al. A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death Dis. 2021;12(2):1–16. doi:10.1038/s41419-021-03447-8
   Web of Science ®Google Scholar
• Mulligan G, Lichter DI, Di Bacco A, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. J Am Soc Hematol. 2014;123:632–639.
   Google Scholar
• Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862–869. doi:10.1158/2159-8290.CD-13-0014
   PubMed Web of Science ®Google Scholar
• Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126(13):1536–1543. doi:10.1182/blood-2015-06-653261
   PubMed Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587–597. doi:10.1182/blood-2018-03-840132
   Web of Science ®Google Scholar